Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ATP2A2 | P16615 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.72 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.72 |
| ▸ | PGR | P06401 | 2/20 | 0.51 |
| ▸ | KIF11 | P52732 | 3/20 | 0.49 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.45 |
| ▸ | GPR18 | Q14330 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paxilline SCHEMBL25011262 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| Paxilline SCHEMBL5955728 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| Paxilline SCHEMBL25470663 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| Paxilline SCHEMBL25470668 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL29934798 | 0.90 | MAPT (0.81) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| Paxilline SCHEMBL20857134 | 0.88 | MAPT (0.78) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL13883195 | 0.86 | MAPT (0.76) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL22953608 | 0.86 | MAPT (0.75) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL25470659 | 0.83 | MAPT (0.70) | MAPTMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL25470665 | 0.83 | MAPT (0.70) | MAPTMEN1KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043908-A1 | COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS | ALLTECH, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-12390473-B2 | Methods of treating tyrosine kinase inhibitor-induced diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-08-19 | — | — | US | claimed |
| EP-3549580-B1 | ENDOPLASMIC RETICULUM-TARGETING NANOVEHICLES | UNIV NAT CHENG KUNG (TW) | 2024-06-26 | — | — | EP | claimed |
| CN-117858696-A | Antibiotic pharmaceutical composition capable of subcutaneous administration | 上海宝济药业股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-11865103-B2 | Methods of treating disorders associated with glycosylation defective proteins | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-01-09 | — | — | US | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| WO-2023196234-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | NAT UNIV SINGAPORE (SG) | 2023-02-09 | — | — | US | claimed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | claimed |
| EP-1463545-A1 | INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT | Atrium Medical Corporation (US) | 2004-10-06 | — | — | EP | claimed |
| WO-2003105868-A1 | NOVEL MAXI-K CHANNEL BLOCKERS, METHODS OF USE AND PROCESS FOR MAKING THE SAME | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | claimed |
| WO-2003039612-A1 | INTRALUMINAL DEVICE WITH A COATING CONTAINING A THERAPEUTIC AGENT | ATRIUM MEDICAL CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| US-20030032595-A1 | Compositions and methods relating to glucose metabolism, weight control, and food intake | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-13 | — | — | US | claimed |
| WO-2002100248-A2 | COMPOSITIONS AND METHODS RELATING TO GLUCOSE METABOLISM, WEIGHT CONTROL, AND FOOD INTAKE | YALE UNIVERSITY (US) | 2002-12-19 | — | — | WO | claimed |
| EP-0804186-B1 | INDOLE DITERPENE ALKALOID COMPOUNDS | MERCK & CO INC (US) | 2002-04-17 | — | — | EP | claimed |
| EP-0804186-A4 | INDOLE DITERPENE ALKALOID COMPOUNDS | MERCK & CO INC (US) | 1998-04-22 | — | — | EP | claimed |
| EP-0804186-A1 | INDOLE DITERPENE ALKALOID COMPOUNDS | MERCK & CO. INC. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1995019771-A1 | INDOLE DITERPENE ALKALOID COMPOUNDS | MERCK & CO., INC. (US) | 1995-07-27 | — | — | WO | claimed |
| US-4973601-A | METABOLITES CONTAINING INDOLE GROUP | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1990-11-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | UBE3A, UBE3C, UBQLN1 | MAPT 1618/4885MEN1 2788/4885KMT2A 216/4885 |
| US-12390473-B2 | Methods of treating tyrosine kinase inhibitor-induced diarrhea | CFTR, LCK, ABL1 | MAPT 4361/4885MEN1 3449/4885KMT2A 2391/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | MAPT 1725/4885MEN1 2772/4885KMT2A 51/4885 |
| US-11865103-B2 | Methods of treating disorders associated with glycosylation defective proteins | MAN1B1, MAN2B1, GBA3 | MAPT 2606/4885MEN1 4128/4885KMT2A 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.